IL148401A0 - Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases - Google Patents

Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases

Info

Publication number
IL148401A0
IL148401A0 IL14840102A IL14840102A IL148401A0 IL 148401 A0 IL148401 A0 IL 148401A0 IL 14840102 A IL14840102 A IL 14840102A IL 14840102 A IL14840102 A IL 14840102A IL 148401 A0 IL148401 A0 IL 148401A0
Authority
IL
Israel
Prior art keywords
hsp70
diagnosis
treatment
autoimmune diseases
derived peptides
Prior art date
Application number
IL14840102A
Other languages
English (en)
Original Assignee
Hadasit Med Res Service
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Yeda Res & Dev filed Critical Hadasit Med Res Service
Priority to IL14840102A priority Critical patent/IL148401A0/xx
Publication of IL148401A0 publication Critical patent/IL148401A0/xx
Priority to EP03710171A priority patent/EP1481003A2/en
Priority to CA002483556A priority patent/CA2483556A1/en
Priority to US10/505,848 priority patent/US20060089302A1/en
Priority to PCT/IL2003/000143 priority patent/WO2003072598A2/en
Priority to AU2003214591A priority patent/AU2003214591A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL14840102A 2002-02-26 2002-02-26 Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases IL148401A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL14840102A IL148401A0 (en) 2002-02-26 2002-02-26 Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
EP03710171A EP1481003A2 (en) 2002-02-26 2003-02-24 Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases
CA002483556A CA2483556A1 (en) 2002-02-26 2003-02-24 Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases
US10/505,848 US20060089302A1 (en) 2002-02-26 2003-02-24 Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
PCT/IL2003/000143 WO2003072598A2 (en) 2002-02-26 2003-02-24 Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases
AU2003214591A AU2003214591A1 (en) 2002-02-26 2003-02-24 Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14840102A IL148401A0 (en) 2002-02-26 2002-02-26 Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
IL148401A0 true IL148401A0 (en) 2002-09-12

Family

ID=27764140

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14840102A IL148401A0 (en) 2002-02-26 2002-02-26 Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases

Country Status (6)

Country Link
US (1) US20060089302A1 (xx)
EP (1) EP1481003A2 (xx)
AU (1) AU2003214591A1 (xx)
CA (1) CA2483556A1 (xx)
IL (1) IL148401A0 (xx)
WO (1) WO2003072598A2 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230181A1 (en) * 2002-05-21 2003-12-02 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
AU2005244852B2 (en) 2004-05-12 2011-09-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
AU2011265315B2 (en) * 2004-05-12 2014-08-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
US20090176245A1 (en) * 2006-03-02 2009-07-09 National University Corporation Chiba University Rheumatoid Arthritis Test Method and Treating Method
EP2170361B1 (en) * 2007-07-06 2016-05-25 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
CN101602793B (zh) * 2008-06-12 2013-06-19 陕西麦科奥特科技有限公司 用于预防和/或治疗类风湿性关节炎的免疫调节多肽及其应用
CA3004867C (en) 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
US9267945B2 (en) 2008-11-12 2016-02-23 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
WO2010086418A1 (en) * 2009-01-29 2010-08-05 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof
EP3109638A1 (en) * 2009-08-03 2016-12-28 Yeda Research And Development Co. Ltd. Urinary biomarkers for cancer diagnosis
WO2011150086A2 (en) * 2010-05-25 2011-12-01 The Regents Of The University Of Colorado, A Body Corporate Diagnosis and treatment of autoimmune disease
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
KR102638203B1 (ko) 2014-09-15 2024-02-19 제브라 덴마크 에이/에스 아리모클로몰 제제
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
BR112018070653A2 (pt) 2016-04-29 2019-02-05 Orphazyme As ingrediente farmacêutico ativo, e, composição
JP2024500632A (ja) 2020-11-19 2024-01-10 ゼブラ デンマーク エー／エス アリモクロモルクエン酸塩及びその中間体の調製プロセス

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
FR2777890B1 (fr) * 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
US7517948B2 (en) * 2000-09-13 2009-04-14 Multimmune Gmbh Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof

Also Published As

Publication number Publication date
WO2003072598A3 (en) 2003-12-24
CA2483556A1 (en) 2003-09-04
AU2003214591A1 (en) 2003-09-09
US20060089302A1 (en) 2006-04-27
WO2003072598A2 (en) 2003-09-04
EP1481003A2 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
HK1068885A1 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases n--
HK1109160A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
IL160917A0 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
EP1572741A4 (en) DIAGNOSTIC AND THERAPEUTIC AGENTS
AU2003298911A8 (en) Cyclosporins for the treatment of autoimmune diseases
EP1692305A4 (en) DIAGNOSIS AND TREATMENT OF DISEASES CAUSED BY DEFECTS IN THE BOUTNEVILLE TUBEREUSE SCLEROSIS PATHWAY
SK18142000A3 (sk) Použitie cyklosporínov na liečenie zápalových autoimunitných ochorení
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
GB0216972D0 (en) Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
AU2003295343A8 (en) Uses of human zven proteins and polynucleotides
AU2003268295A8 (en) "diagnosis and treatment of infertility"
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2002362383A1 (en) Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
GB0402129D0 (en) Therapeutic and diagnostic peptides
AU2003240253A1 (en) Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
EP1483407A4 (en) THERAPY AND DIAGNOSTIC PROCEDURES
AU2003265867A8 (en) A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
AU2003286530A8 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease